Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Systemic reactions to allergen immunotherapy: a role for measuring a PGD2 metabolite?

Rank MA, Kita H, Li JT, Butterfield JH.

Ann Allergy Asthma Immunol. 2013 Jan;110(1):57-8. doi: 10.1016/j.anai.2012.10.009. Epub 2012 Nov 8. No abstract available.

PMID:
23244662
2.
3.

Stable 9 beta- or 11 alpha-halogen-15-cyclohexyl-prostaglandins with high affinity to the PGD2-receptor.

Thierauch KH, Stürzebecher CS, Schillinger E, Rehwinkel H, Radüchel B, Skuballa W, Vorbrüggen H.

Adv Prostaglandin Thromboxane Leukot Res. 1989;19:655-8. No abstract available.

PMID:
2526554
5.

Systemic reactions associated with subcutaneous allergen immunotherapy: timing and risk assessment.

DaVeiga SP, Liu X, Caruso K, Golubski S, Xu M, Lang DM.

Ann Allergy Asthma Immunol. 2011 Jun;106(6):533-537.e2. doi: 10.1016/j.anai.2011.02.007. Epub 2011 Apr 14.

PMID:
21624754
6.

Salicylamide-induced anaphylaxis: increased urinary leukotriene E4 and prostaglandin D2 metabolite.

Ono E, Taniguchi M, Mita H, Akiyama K.

Allergy. 2008 Apr;63(4):480-2. doi: 10.1111/j.1398-9995.2007.01616.x. No abstract available.

7.

Patient perceptions regarding local reactions from allergen immunotherapy injections.

Coop CA, Tankersley MS.

Ann Allergy Asthma Immunol. 2008 Jul;101(1):96-100. doi: 10.1016/S1081-1206(10)60841-1.

PMID:
18681091
8.

Incidence and characteristics of biphasic reactions after allergen immunotherapy.

Scranton SE, Gonzalez EG, Waibel KH.

J Allergy Clin Immunol. 2009 Feb;123(2):493-8. doi: 10.1016/j.jaci.2008.10.026. Epub 2008 Dec 6.

PMID:
19064282
9.

Plasma 9alpha,11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma.

Bochenek G, Nizankowska E, Gielicz A, Swierczyńska M, Szczeklik A.

Thorax. 2004 Jun;59(6):459-64.

10.

Formation of PGD2 after allergen inhalation in atopic asthmatics.

Sladek K, Sheller JR, FitzGerald GA, Morrow JD, Roberts LJ 2nd.

Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:433-6. No abstract available.

PMID:
1847781
11.

Survey of aspirin administration in systemic mastocytosis.

Butterfield JH.

Prostaglandins Other Lipid Mediat. 2009 Apr;88(3-4):122-4. doi: 10.1016/j.prostaglandins.2009.01.001. Epub 2009 Jan 22.

PMID:
19429499
12.

The REPEAT study: recognizing and evaluating periodic local reactions in allergen immunotherapy and associated systemic reactions.

Calabria CW, Stolfi A, Tankersley MS.

Ann Allergy Asthma Immunol. 2011 Jan;106(1):49-53. doi: 10.1016/j.anai.2010.10.025.

PMID:
21195945
13.

The release of prostaglandin D2 from human skin in vivo and in vitro during immediate allergic reactions.

Barr RM, Koro O, Francis DM, Black AK, Numata T, Greaves MW.

Br J Pharmacol. 1988 Jul;94(3):773-80.

14.

The metabolism of prostaglandin D2. Evidence for the sequential conversion by NADPH and NAD+ dependent pathways.

Robinson C, Herbert CA, Bedwell S, Shell DJ, Holgate ST.

Biochem Pharmacol. 1989 Oct 1;38(19):3267-71.

PMID:
2818626
15.
16.

Comparative vascular effects of histamine, prostaglandin (PG) D2 and its metabolite 9 alpha,11 beta-PGF2 in human skin.

Beasley R, Hovel C, Mani R, Robinson C, Varley J, Holgate ST.

Clin Allergy. 1988 Nov;18(6):619-27.

PMID:
3242978
18.
19.

Permeability of brain structures and other peripheral tissues to prostaglandins D2, E2 and F2 alpha in rats.

Eguchi N, Kaneko T, Urade Y, Hayashi H, Hayaishi O.

J Pharmacol Exp Ther. 1992 Sep;262(3):1110-20.

PMID:
1527717
20.

Supplemental Content

Support Center